Bionomics Limited (BNO.AX)
| Previous close | 0.0290 |
| Open | 0.0300 |
| Bid | 0.0290 x 2640300 |
| Ask | 0.0310 x 16362900 |
| Day's range | 0.0300 - 0.0310 |
| 52-week range | 0.0280 - 0.0980 |
| Volume | |
| Avg. volume | 674,160 |
| Market cap | 40.6M |
| Beta (5Y monthly) | 2.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0170 |
| Earnings date | 21 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.00 |
- GlobeNewswire
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to PlaceboBNC210 Demonstrated Favourable Safety and Tolerability Profile Consistent with Prior ExperienceCompany is Continuing Analysis of the Data and Evaluating Next Steps with Cash Runway into mid-2024 ADELAIDE, Australia, Dec. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (B
- GlobeNewswire
Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer
Experienced biotech executive to lead the next phase of growthADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it has appointed Spyridon “Spyros” Papapetropoulos, M.D. as
- GlobeNewswire
Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders, today announced it will present data on the development of an oral tablet formulation of BNC210 for the treatment of Social Anxiety Disorder (SAD) and data on the pharmacometr
